SCHEMBL13405239

SCHEMBL13405239

CN[C@H](Cc1ccccc1)CN1CCC(F)(F)C1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 2/20 0.41
SLC18A2 Q05940 1/20 0.41
SIGMAR1 Q99720 1/20 0.41
HDAC8 Q9BY41 2/20 0.39
ALDH1A1 P00352 1/20 0.36
CYP2D6 P10635 1/20 0.36
GRIN2D O15399 1/20 0.36
GRIN3B O60391 1/20 0.36
ADRA1D P25100 1/20 0.36
ADRA1A P35348 1/20 0.36
ADRA1B P35368 1/20 0.36
GRIN1 Q05586 1/20 0.36
GRIN2A Q12879 1/20 0.36
GRIN2B Q13224 1/20 0.36
GRIN2C Q14957 1/20 0.36
GRIN3A Q8TCU5 1/20 0.36
OPRL1 P41146 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9769074 0.78 LTA4H (0.49) TAAR1SLC18A2SIGMAR1CYP2D6
SCHEMBL16379681 0.78 NOX1 (0.38) ALDH1A1CYP2D6OPRL1
SCHEMBL19258136 0.74 SIGMAR1 (0.46) TAAR1SLC18A2SIGMAR1ALDH1A1CYP2D6
SCHEMBL19258005 0.74 SIGMAR1 (0.46) TAAR1SLC18A2SIGMAR1ALDH1A1CYP2D6
SCHEMBL27033000 0.74 DPP4 (0.45) ALDH1A1CYP2D6
SCHEMBL3992623 0.73 CYP3A4 (0.56) SIGMAR1ALDH1A1CYP2D6OPRL1
Hydrochloric Acid SCHEMBL25412712 0.71 CYP3A4 (0.54) SIGMAR1ALDH1A1CYP2D6OPRL1
SCHEMBL13405085 0.71 SLC6A4 (0.44) TAAR1SIGMAR1HDAC8CYP2D6
SCHEMBL1697045 0.70 SIGMAR1 (0.64) TAAR1SLC18A2SIGMAR1CYP2D6
SCHEMBL8276883 0.70 ARG1 (0.39) ALDH1A1OPRL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7704996-B2 Compounds and compositions useful as cathepsin S inhibitors NOVARTIS AG (CH) 2010-04-27 US disclosed
US-7704996-B2 Compounds and compositions useful as cathepsin S inhibitors NOVARTIS AG (CH) 2010-04-27 US disclosed
US-20090048230-A1 COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS NOVARTIS AG (CH) 2009-02-19 US disclosed
US-20090048230-A1 COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS NOVARTIS AG (CH) 2009-02-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048230-A1 COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS CTSS, CTSZ, CTSF TAAR1 3386/4885SLC18A2 2924/4885SIGMAR1 4070/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.